An Epidemiological Study on Antimicrobial Treatment of Nosocomial Infections in Clinical Practice
NCT ID: NCT00864929
Last Updated: 2011-02-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1500 participants
OBSERVATIONAL
2009-11-30
2010-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Mortality Related to AMR in Patients With Hospital-acquired Infection
NCT03411538
Preauthorization Versus Prospective Audit in Antimicrobial Stewardship Program
NCT02837081
COVID-19 - Multicenter Study on Nosocomial Transmission of SARS-CoV-2 Virus
NCT04290780
Microbial Etiology of Ventilator-associated Pneumonia in COVID-19 Infected Patients
NCT04344509
Antimicrobial Stewardship in Community Hospitals
NCT02212808
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Appropriate antimicrobial treatment
No interventions assigned to this group
2
Inappropriate antimicrobial treatment
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient received empiric antimicrobial therapy within 24 hour from onset of infection and had antimicrobial susceptibility.
Exclusion Criteria
* Patients with suspected infections by virus or fungus or tuberculosis will be excluded.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca Vietnam
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Phan Anh Tuan Nguyen, MD
Role: STUDY_DIRECTOR
AstraZeneca Vietnam
To Nhu Le, MD
Role: PRINCIPAL_INVESTIGATOR
National Paediatric Insitute
Viet Hoa Le
Role: PRINCIPAL_INVESTIGATOR
The 108 Military Central Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Hanoi, , Vietnam
Research Site
Ho Chi Minh City, , Vietnam
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIS-IVN-DUM-2008/1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.